Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

This study has been completed.
Sponsor:
Collaborator:
INC Research
Information provided by (Responsible Party):
Medicago
ClinicalTrials.gov Identifier:
NCT01244867
First received: November 15, 2010
Last updated: July 30, 2012
Last verified: July 2012
  Purpose

The primary objective is to assess the immunogenicity and safety and tolerability of two consecutive doses of H5 VLP Influenza vaccine given 21 days apart, at three dose levels: in part A: 20 µg, 30 µg and 45 µg combined with Alhydrogel® 1%, or 45 µg without Alhydrogel®, compared to the placebo, (100mM phosphate buffer + 150mM NaCl + 0.01% Tween 80).


Condition Intervention Phase
Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Biological: 20 micrograms dose H5 VLP
Biological: 30 micrograms dose H5 VLP
Biological: 45 micrograms dose H5 VLP
Biological: 45 micrograms non-adjuvanted H5 VLP
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.

Resource links provided by NLM:


Further study details as provided by Medicago:

Primary Outcome Measures:
  • Immunogenicity [ Time Frame: 21 days after each injection and 6-month follow-up period ] [ Designated as safety issue: No ]
    Immunogenicity Geometric mean titres: (GMTs) of hemagglutination inhibition (HI) antibody on Days 0, 21 and 42. Follow-up serology samples for GMTs will be taken at Day 228.

  • Safety [ Time Frame: 21 days after each vaccination and 6-month follow-up ] [ Designated as safety issue: Yes ]
    Safety will be assessed by the rate and severity of solicited and unsolicited adverse events post-vaccination. A 6-month follow-up period will be performed.


Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: 21 dyas after each injection ] [ Designated as safety issue: No ]
    The secondary objective is to assess the cross-reactivity of antibodies induced by two consecutive doses of H5 VLP influenza vaccine given 21 days apart, at three dose levels: 20 µg, 30 µg and 45 µg combined with Alhydrogel® 1%, or 45 µg without Alhydrogel® 1% as measured by HI antibody titers for the A/Vietnam/1203/04, A/Anhui/01/2005 and A/turkey/Turkey/1/05 H5N1 strains and as measured by MicroNeutralisation(MN) antibody titers for the A/Indonesia/5/05 and A/Vietnam/1203/04 H5N1 strains.


Enrollment: 255
Study Start Date: November 2010
Study Completion Date: September 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 20 microgram H5 VLP vaccine + Alhydrogel Biological: 20 micrograms dose H5 VLP
2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
Experimental: 30 micrograms H5 VLP vaccine + Alhydrogel Biological: 30 micrograms dose H5 VLP
2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
Experimental: 45 micrograms H5 VLP vaccine + Alhydrogel Biological: 45 micrograms dose H5 VLP
2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
Experimental: 45 micrograms H5 VLP vaccine Biological: 45 micrograms non-adjuvanted H5 VLP
2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
Placebo Comparator: Placebo Biological: Placebo
2 doses given 21 days apart of the placebo

Detailed Description:

An adaptive design is proposed for this phase 2 trial. Part A of this study will consist of dose-ranging in 135 subjects who will be randomized to receive one injection of either 20 µg, 30 µg or 45 µg H5 VLP Influenza vaccine combined with Alhydrogel®, or 45 µg without Alhydrogel®, or the placebo preparation, (100mM phosphate buffer + 150mM NaCl + 0.01% Tween 80) at Days 0 and 21. Seven-day (7) safety data after the first immunization for subjects in all five treatment groups will be tabulated and reviewed by a panel consisting of 2 external medical advisors, prior to permitting the second immunization of vaccine/placebo for all treatment groups at Day 21 (Part A). Twenty-one (21) days after the last subject vaccine administration in Part A, all safety and immunogenicity data will be collected and analysed to determine the optimal dose level. Following selection of the optimal dose, Part B of the trial will commence and consist of administration of the selected optimal dose(s) in one hundred (100) subjects, plus administration of placebo in twenty (20) subjects (total of 120 subjects in part B). These subjects will similarly receive two vaccinations 21 days apart and will be followed in the exact same fashion as Part A, except that there will be no 7-day safety analysis. Depending on data analysis one or a maximum of two vaccine doses could be selected to be further evaluated during part B of the trial. All Part A and B subjects will be followed for safety until Day 228.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male and female adults, 18 to 60 years of age;
  • Healthy as judged by the Principal Investigator (PI) and determined by medical history, physical examination, vital signs, screening laboratories and medical history conducted no more than 30 days prior to study vaccine administration;
  • BMI of ≥18 and ≤ 32;
  • Comprehension of the study requirements, expressed availability for the required study period and ability to attend scheduled visits;
  • Accessible by telephone on a consistent basis;
  • In the opinion of the Investigator, competence and willingness to provide written, informed consent for participation after reading the informed consent form. The subject must have adequate opportunity to discuss the study with an Investigator or qualified designee;
  • If female and capable of child-bearing, have a negative serum pregnancy test result at study entry, has been consistently using effective birth control for the 28 days prior to study entry and agree to continue employing adequate birth control measures for the duration of the study.

Exclusion Criteria:

  • Presence of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. "Uncontrolled" is defined as:

    1. Requiring a new medical or surgical treatment within one month prior to study vaccine administration;
    2. Requiring a change in medication dosage in one month prior to test article administration due to uncontrolled symptoms or drug toxicity (elective dosage adjustments in stable subjects are acceptable), or
    3. Hospitalization or an event fulfilling the definition of a serious adverse event within one month prior to test article administration;
  • Any medical or neuropsychiatric condition which, in the Investigator's opinion, would render the subject incompetent to provide informed consent or unable to provide valid safety observations and reporting;
  • Any confirmed or suspected immunosuppressive condition or immunodeficiency including history of human immunodeficiency virus (HIV) infection or Hepatitis B or C or presence of lymphoproliferative disease;
  • Presence of any febrile illness, oral temperature of >38.0˚C within 24 hours of test article administration. Such subjects may be re-evaluated for enrolment after resolution of illness;
  • History of autoimmune disease;
  • Administration of any vaccine (including any other influenza vaccine) within a 30 day period prior to study enrolment, or planned administration within the period from the first vaccination up to blood sampling at Day 42 or within 30 days prior to blood sampling at Day 228. Immunization on an emergency basis of a tetanus and diphtheria toxoids adsorbed for adult use (Td) will be allowed provided the vaccine is not administered within two weeks prior to test article administration. Receipt of any other emergency immunizations (e.g. rabies) will result in a case-by-case review of continued participation;
  • Use of any investigational or non-registered product within 30 days prior to study enrolment or planned use during the study period. Subjects may not participate in any other drug study while participating in this study;
  • Treatment with systemic glucocorticoids at a dose exceeding ≥ 10 mg of prednisone per day, or equivalent for more than 7 consecutive days or for 10 or more days in total, within one month of first test article administration, or any other cytotoxic or immunosuppressant drug or any immune globulin preparation within three months of vaccination. Nasal or inhaled glucocorticoids are allowed;
  • Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin. Persons receiving prophylactic anti-platelet medications, e.g., low-dose aspirin, and without a clinically apparent bleeding tendency are eligible;
  • History of previous H5N1 vaccination or a history of exposure to H5N1 virus;
  • History of allergy to any of the constituents of H5 VLP (H5N1) study vaccine, Alhydrogel® (aluminum hydroxide), or the phosphate buffer;
  • History of severe allergic reactions or anaphylaxis;
  • History of tobacco allergy;
  • History of anti-histaminics used continuously for 4 weeks or more at any time in the past year;
  • Have a rash, dermatological condition or tattoos which may interfere with injection site reaction rating;
  • Have received a blood transfusion or immunoglobulins within 90 days of study entry;
  • If female, and of childbearing potential, has not been consistently using effective birth control for the 28 days prior to study entry. An example of highly effective birth control is oral contraceptives, hormone implants, abstinence (confirmed by Investigator), or male condom plus spermicide. All female subjects, regardless of birth control history must provide a serum sample for pregnancy screening. Effective birth control must be used for the duration of the study for female of child bearing potential must have no plan to become pregnant during the study period.;
  • Among female subjects, either known pregnancy or urine beta-human chorionic gonadotropin (ß-hCG) test results consistent with pregnancy prior to test article administration on Day 0;
  • Female subjects who are lactating;
  • Vital sign abnormalities: systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥90 mmHg, resting pulse rate <40 bpm or >100 bpm or according to the Investigator's opinion;
  • Cancer or treatment for cancer within 3 years of test article administration. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin are eligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01244867

Locations
Canada, Ontario
Kendle Early Stage
Toronto, Ontario, Canada, M5V 2T3
Sponsors and Collaborators
Medicago
INC Research
Investigators
Principal Investigator: Edward M. Sellers, MD Kendle Early Stage Toronto Canada
  More Information

No publications provided

Responsible Party: Medicago
ClinicalTrials.gov Identifier: NCT01244867     History of Changes
Other Study ID Numbers: CP-H5VLP-002
Study First Received: November 15, 2010
Last Updated: July 30, 2012
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Communicable Diseases
Infection
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases
Aluminum Hydroxide
Adjuvants, Immunologic
Antacids
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 25, 2014